Quantitative evaluation of Alzheimer's disease

Expert Review of Medical Devices

Volumn 6, Issue 5, 2009, Pages 569-588

  Caroli, Anna ^a,b   Frisoni, Giovanni B ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer's disease; Diagnosis; Markers; Multimodal imaging; Neuroimaging; Quantification

Indexed keywords

BIOLOGICAL MARKER; FLUORINE 18;

ALZHEIMER DISEASE; AMYLOIDOSIS; BRAIN ATROPHY; BRAIN DYSFUNCTION; BRAIN SIZE; BRAIN TISSUE; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; COMPUTER ASSISTED DIAGNOSIS; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MILD COGNITIVE IMPAIRMENT; MORPHOMETRICS; MULTIINFARCT DEMENTIA; NEUROANATOMY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RATING SCALE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; DIAGNOSTIC IMAGING; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NEURORADIOGRAPHY;

EID: 70449365482     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.35     Document Type: Review

References (150)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of AD: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on AD. Neurology 34, 939-944 (1984).
2. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive imapirment in elderly primary care patients. Ann. Intern. Med. 122, 422-429 (1995).
3. Hoffman RS. Diagnostic errors in the evaluation of behavioral disorders. JAMA 248, 964-967 (1982).
4. Lim A, Tsuang D, Kukull W et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J. Am. Geriatr. Soc. 47, 564-569 (1999). (Pubitemid 29215585)
5. McDaniel LD, Lukovits T, McDaniel KD. Alzheimer's disease: the problem of incorrect clinical diagnosis. J. Geriatr. Psychiatry Neurol. 6, 230-234 (1993).
6. Small AS. Alzheimer disease, in living color. Nat. Neurosci. 8, 404-405 (2005).
7. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746 (2007). •• Recent revision of the diagnostic criteria for Alzheimer's disease (AD), requiring quantitative evaluation of several biomarkers for AD. (Pubitemid 47058377)
8. Duara R, Loewenstein DA, Potter E et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71, 1986-1992 (2008).
9. Frisoni GB, Galluzzi S, Pantoni L, Filippi M. The effect of white matter lesions on cognition in the elderly - small but detectable. Nat. Clin. Pract. Neurol. 3, 620-627 (2007). (Pubitemid 350048228)
10. Scheltens P, Leys D, Barkhof F et al. Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatry 55, 967-972 (1992).
11. Wahlund LO, Julin P, Johansson SE, Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J. Neurol. Neurosurg. Psychiatry 69, 630-635 (2000). (Pubitemid 30802089)
12. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J. Neurol. Neurosurg. Psychiatry 72, 491-497 (2002). (Pubitemid 34289566)
13. DeCarli C, Frisoni GB, Clark CM et al. Alzheimer's Disease Cooperative Study Group. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch. Neurol. 64, 108-115 (2007).
14. Galluzzi S, Lanni C, Pantoni L, Filippi M, Frisoni GB. White matter lesions in the elderly: pathophysiological hypothesis on the effect on brain plasticity and reserve. J. Neurol. Sci. 273, 3-9 (2008)
15. Scheltens P, Erkinjunti T, Leys D et al. White matter changes on CT and MRI: an overview of visual rating scales. European task force on age-related white matter changes. Eur. Neurol. 39, 80-89 (1998).
16. Wahlund LO, Barkhof F, Fazekas F et al.; European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32, 1318-1322 (2001).
17. Laakso MP, Partanen K, Riekkinen P et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 46, 678-681 (1996). (Pubitemid 26099632)
18. Laakso MP, Soininen H, Partanen K et al. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol. Aging 19, 23-31 (1998). (Pubitemid 28167791)
19. Devanand DP, Pradhaban G, Liu X et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68, 828-836 (2007). (Pubitemid 46568534)
20. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm. Suppl. 53, 127-140 (1998). (Pubitemid 28361774)
21. Pennanen C, Kivipelto M, Tuomainen S et al. Hippocampus and enthorinal cortex in mild cognitive impairment and early AD. Neurobiol. Aging 25, 303-310 (2004). (Pubitemid 38220965)
22. Du AT, Schuff N, Zhu XP et al. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology 60, 481-486 (2003). (Pubitemid 36188246)
23. DeCarli C, Maisog J, Murphy DG, Teichberg D, Rapoport SI, Horwitz B. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J. Comput. Assist. Tomogr. 16, 274-284 (1992).
24. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch. Neurol. 58, 643-647 (2001). (Pubitemid 32295717)
25. Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM. Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet. Neurol. 2, 79-88 (2003). (Pubitemid 37443328)
26. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage.14, 805-821 (2000).
27. Lerch JP, Pruessner JC, Zijdenbos et al. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb. Cortex 15, 995-1001 (2005).
28. Thompson PM, Mega MS, Toga AW. Disease-specific brain atlases. In: Brain Mapping: the Disorders. Toga AW, Mazziotta JC (Eds). Academic Press, London, UK, 131-177 (2000).
29. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput. Methods Programs Biomed. 53, 15-25 (1997).
30. Frisoni GB, Testa C, Zorzan A et al. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry. J. Neurol. Neurosurg. Psychiatry 73, 657-664 (2002). (Pubitemid 35448849)
31. Karas GB, Burton EJ, Rombouts SA et al. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage 18, 895-907 (2003).
32. Chetelat G, Landeau B, Eustache F. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 27, 934-946 (2005). (Pubitemid 41317262)
33. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum. Brain Mapp. 15, 1-25 (2002).
34. Thompson PM, Toga AW. A surface-based technique for warping 3-dimensional images of the brain. IEEE Trans. Med. Imaging 15, 1-16 (1996).
35. Thompson PM, Cannon TD, Narr KL et al. Genetic influences on brain structure. Nat. Neurosci. 4, 1253-1258 (2001).
36. Davatzikos C. Spatial normalization of 3D brain images using deformable models. J. Comput. Assist. Tomogr. 20, 656-665 (1996). (Pubitemid 26244429)
37. Thompson PM, Hayashi KM, de Zubicaray G et al. Detecting dynamic and genetic effects on brain structure using high-dimensional cortical pattern matching. Presented at: The International Symposium on Biomedical Imaging. Washington, DC, USA, 7-10 July 2002.
38. Thompson PM, Mega MS, Woods RP et al. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb. Cortex 11, 1-16 (2001).
39. Frisoni GB, Pievani M, Testa C et al. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 130, 720-730 (2007). (Pubitemid 46410740)
40. Thompson PM, Hayashi KM, de Zubicaray G et al. Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 23, 994-1005 (2003).
41. Frisoni GB, Prestia A, Rasser PE et al. In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease. J. Neurol. 256(6), 916-924 (2009).
42. Lerch JP, Pruessner JC, Zijdenbos A et al. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb. Cortex 15, 995-1001 (2005). (Pubitemid 40848068)
43. Frisoni GB, Sabattoli F, Lee AD, Dutton RA, Toga AW, Thompson PM. In vivo neuropathology of the hippocampal formation in AD: a radial mapping MR-based study. Neuroimage 32, 104-110 (2006).
44. Frisoni GB, Ganzola R, Canu E et al. Mapping local hippocampal changes in Alzheimer's disease and normal aging with MRI at 3 Tesla. Brain 131, 3266-3276 (2008). • Uses a sophisticated computerized algorithm, pointing out a key role for MRI in the evaluation of morphostructural changes in AD.
45. Fox NC, Cousens S, Scahill R et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer Disease. Arch. Neurol. 57, 339-344 (2000).
46. Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 348, 94-97 (1996).
47. Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J. Magn. Reson. Imaging 7, 1069-1075 (1997).
48. Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalised accurate measurement of longitudinal brain change. J. Comput. Assist. Tomogr. 25, 466-475 (2001). (Pubitemid 32440803)
49. DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 36, 50-55 (2005). (Pubitemid 40054174)
50. Yoshita M, Fletcher E, Harvey D et al. Extent and distribution of white matter hyperintensities in normal aging, MCI and AD. Neurology 67, 2192-2198 (2006). • Shows white matter hyperintensity extent and distribution in the different stages of cognitive impairment. (Pubitemid 46035476)
51. Bonte FJ, Devous MD Sr, Holman BL. Single photon emission computed tomographic imaging of the brain. In: Diagnostic Nuclear Medicine 4th edition. Sandler MP, Coleman RE, Wackers FJ, Patton JA, Gottschalk A, Hoffer PB (Eds). Williams and Wilkins, MD, USA (2004).
52. Jagust W, Thisted R, Devous MD Sr et al. SPECT perfusion imaging in the diagnosis of AD: a clinical-pathologic study. Neurology 56, 950-956 (2001). (Pubitemid 32290814)
53. Mielke R, Pietrzyk U, Jacobs A et al. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur. J. Nucl. Med. 21, 1052-1060 (1994). (Pubitemid 24304430)
54. Messa C, Perani D, Lucignani G et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. J. Nucl. Med. 35, 210-216 (1994). (Pubitemid 24048307)
55. Mielke R, Heiss WD. Positron emission tomography for diagnosis of AD and vascular dementia. J. Neural. Transm. 53, 237-250 (1998). (Pubitemid 28361784)
56. Mosconi L, Mistur R, Switalski R et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's Disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811-822 (2009). •• Recent longitudinal FDG-PET study in postmortem verified normal controls followed to the onset of AD and in patients with progressive AD, proving the validity of fluorodeoxyglucose-PET imaging for early diagnosis.
57. de Leon MJ, Ferris SH, George A et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J. Cereb. Blood. Flow Metab. 3, 391-394 (1993).
58. Foster NL, Chase TN, Mansi L et al. Cortical abnormalities in Alzheimer's disease. Ann. Neurol. 16, 649-654 (1984).
59. Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet 26, 228 (1985). (Pubitemid 15151499)
60. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT. Alzheimer disease: operating characteristics of PET - a meta-analysis. Radiology 231, 73-80 (2004).
61. 18F]fluoro-2-deoxy-D-glucose/ positron-emission tomography (FDG/PET). Proc. Natl Acad. Sci. USA 98, 10966-10971 (2001).
62. De Santi S, de Leon MJ, Rusinek H et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 22, 529-539 (2001). (Pubitemid 32607736)
63. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann. Neurol. 54, 343-351 (2003). (Pubitemid 37072036)
64. Mosconi L, De Santi S, Li J et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging 29, 676-692 (2008)
65. Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM. Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol. 2, 79-88 (2003). (Pubitemid 37443328)
66. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ. Comparing functional (PET) images: the assessment of significant change. J. Cereb. Blood. Flow Metab. 11, 690-699 (1991).
67. Friston K, Ashburner J, Frith C, Poline J-B, Heather J, Frackowiak R. Spatial registration and normalization of images. Hum. Brain Mapp. 3, 165-189 (1995).
68. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 36, 1238-1248 (1995).
69. Caroli A, Geroldi C, Nobili F et al. Functional compensation in incipient Alzheimer's disease. Neurobiol. Aging DOI:10.1016/j.neurobiolaging.2008.05.001 (2008) (Epub ahead of print).
70. Herholz K, Salmon E, Perani D et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17, 302-316 (2002).
71. Barber R, Snowden JS, Craufurd D. Frontotemporal dementia and Alzheimer's disease: retrospective differentiation using information from informants. J. Neurol. Neurosurg. Psychiatr. 59, 61-70 (1995).
72. Ishii K, Imamura T, Sasaki M et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 51, 125-130 (1998). (Pubitemid 28345371)
73. 18F-fluoro-2-deoxy-d-glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. Eur. J. Neurol. 45, 19-27 (2001).
74. Foster NL, Heidebrink JL, Clark CM et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 130, 2616-2635 (2007)
75. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann. Neurol. 50, 358-365 (2001). (Pubitemid 32848738)
76. Albin RL, Minoshima S, Damato CJ, Frey KA, Kuhl DE, Sima AAF. Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 47, 462-466 (1996). (Pubitemid 26324044)
77. Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 54, 1304-1309 (2000). (Pubitemid 30174051)
78. Szelies B, Mielke R, Herholz K, Heiss W-D. Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. Electroencephalogr. Clin. Neurophysiol. 91, 131-139 (1994). (Pubitemid 24246467)
79. Guze BH, Baxter LR, Schwartz JM, Szuba MP, Mazziotta JC, Phelps ME. Changes in glucose metabolism in dementia of the Alzheimer type compared with depression: a preliminary report. Psychiatry Res. 40, 195-202 (1991).
80. Ebmeier KP, Prentice N, Ryman A et al. Temporal lobe abnormalities in dementia and depression: a study using high resolution single photon emission tomography and magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatr. 63, 597-604 (1997). (Pubitemid 27489223)
81. Ebmeier KP, Glabus M, Prentice N, Ryman A, Goodwin GM. A voxel-based analysis of cerebral perfusion in dementia and depression of old age. Neuroimage 7, 199-208 (1998). (Pubitemid 28372790)
82. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br. J. Radiol. 80, S160-S167 (2007) • Excellent review of PET imaging in dementia. (Pubitemid 351799343)
83. Charpentier P, Lavenu I, Defebvre L et al. Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data. J. Neurol. Neurosurg. Psychiatry. 69, 661-663 (2000). (Pubitemid 30802098)
84. Rombouts SA, Damoiseaux JS, Goekoop R et al. Model-free group analysis shows altered BOLF FMRI networks in dementia. Hum. Brain Mapp. 30, 256-266 (2009).
85. Grossman M, Koenig P, DeVita C et al. Neural basis for verb processing in Alzheimer's disease: an fMRI study. Neuropsychology 17, 658-674 (2003). (Pubitemid 37419984)
86. Machulda MM, Ward HA, Borowski B et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 61, 500-506 (2003). (Pubitemid 37025367)
87. Rombouts SA, van Swieten JC, Pijnenburg YA, Goekoop R, Barkhof F, Scheltens P. Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology 60, 1904-1908 (2003)
88. Sperling RA, Bates JF, Chua EF et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74, 44-50 (2003).
89. Kato T, Knopman D, Liu H. Dissociation of regional activation in mild AD during visual encoding: a functional MRI study. Neurology 57, 812-816 (2001). (Pubitemid 32845500)
90. Rombouts SA, Barkhof F, Veltman DJ et al. Functional MR imaging in Alzheimer's disease during memory encoding. Am. J. Neuroradiol. 21, 1869-1875 (2000).
91. Dickerson BC, Salat DH, Bates JF et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol. 56, 27-35 (2004).
92. Lipton RB, Dodick D, Sadovsky R et al.; ID Migraine validation study. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology 61, 375-382 (2003). (Pubitemid 36975969)
93. Lustig C, Snyder AZ, Bhakta M et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc. Natl Acad. Sci. USA 100, 14504-14509 (2003). (Pubitemid 37499266)
94. Prvulovic D, Hubl D, Sack AT et al. Functional imaging of visuospatial processing in Alzheimer's disease. Neuroimage 17, 1403-1414 (2002). (Pubitemid 35333860)
95. Bookheimer SY, Strojwas MH, Cohen MS et al. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343, 450-456 (2000).
96. Thulborn KR, Martin C, Voyvodic JT. Functional MR imaging using a visually guided saccade paradigm for comparing activation patterns in patients with probable Alzheimer's disease and in cognitively able elderly volunteers. Am. J. Neuroradiol. 21, 524-531 (2000). (Pubitemid 30149346)
97. Saykin AJ, Flashman LA, Frutiger SA et al. Neuroanatomic substrates of semantic memory impairment in Alzheimer's disease: patterns of functional MRI activation. J. Int. Neuropsychol. Soc. 5, 377-392 (1999).
98. Pihlajamäki M, Jauhiainen AM, Soininen H. Structural and functional MRI in mild cognitive impairment. Curr. Alzheimer Res. 6, 179-185 (2009).
99. Liu Y, Wang K, Yu C et al. Regional homogeneity, functional connectivity and imaging markers of Alzheimer's disease: a review of resting-state fMRI studies. Neuropsychologia 46, 1648-1656 (2008). • All-comprehensive review of resting-state functional MRI in AD.
100. Cabeza R. Hemispheric asymmetry reduction in older adults: the HAROLD model. Psychol. Aging 17, 85-100 (2002). (Pubitemid 34241215)
101. Gusnard DA, Raichle ME, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat. Rev. Neurosci. 2, 685-694 (2001).
102. Mazoyer B, Zago L, Mellet E et al. Cortical networks for working memory and executive functions sustain the conscious resting state in man. Brain Res. Bull. 54, 287-298 (2001). (Pubitemid 32273621)
103. McKiernan KA, Kaufman JN, Kucera- Thompson J, Binder JR. A parametric manipulation of factors affecting task-induced deactivation in functional neuroimaging. J. Cogn. Neurosci. 15, 394-408 (2003).
104. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat. Rev. Neurosci. 8, 700-711 (2007).
105. Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum. Brain Mapp. 26, 231-239 (2005). (Pubitemid 41759880)
106. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl. Acad. Sci. USA 101, 4637-4642 (2004). (Pubitemid 38437463)
107. Fleisher AS, Houston WS, Eyler LT et al. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch. Neurol. 62, 1881-1888 (2005).
108. Smith CD, Andersen AH, Kryscio RJ. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53, 1391-1396 (1999).
109. Smith CD, Kryscio RJ, Schmitt FA et al. Longitudinal functional alterations in asymptomatic women at risk for Alzheimer's disease. J. Neuroimaging 15, 271-277 (2005).
110. Haier RJ, Jung RE, Yeo RA, Head K, Alkire MT. Structural brain variation and general intelligence. Neuroimage 23, 425-433 (2004). (Pubitemid 39119473)
111. Gray JR, Thompson PM. Neurobiology of intelligence: science and ethics. Nat. Rev. Neurosci. 5, 471-482 (2004).
112. Kowall NW, Kosik KS. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer 's disease. Ann. Neurol. 22, 639-643 (1987).
113. Stahl R, Dietrich O, Teipel SJ, Hampel H, Reiser MF, Schoenberg SO. White matter damage in Alzheimer 's disease and in mild cognitive impairment: assessment with diffusion tensor MRI using parallel imaging techniques. Radiology 243, 483-492 (2007). • Overview of diffusion tensor imaging in AD. (Pubitemid 46649705)
114. Bozzali M, Falini A, Franceschi M et al. White matter damage in Alzheimer 's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 72, 742-746 (2002). (Pubitemid 34557017)
115. Fellgiebel A, Muller MJ, Wille P et al. Color-coded diffusion-tensor- imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol. Aging 26, 1193-1198 (2005). (Pubitemid 40726012)
116. Medina D, Detoledo-Morrell L, Urresta F et al. White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol. Aging 27, 663-672 (2006).
117. Teipel SJ, Stahl R, Dietrich O et al. Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage 34, 985-995 (2007). (Pubitemid 46049172)
118. Muller MJ, Greverus D, Weibrich C et al. Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiol. Aging 28, 398-403 (2007). (Pubitemid 46177388)
119. Terwel D, Dewachter L, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med. 2, 151-165 (2002). (Pubitemid 37012502)
120. Berg L, McKeel DW Jr, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch. Neurol. 50, 349-358 (1993). (Pubitemid 23105458)
121. Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur. J. Nucl. Med. Mol. Imaging 35, 846-850 (2008).
122. Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC. The ART of loss: Aβ imaging in the evaluation of alzheimer's disease and other dementias. Mol. Neurobiol. 38, 1-15 (2008)
123. Frisoni GB. Imaging of amyloid comes of age. Lancet Neurol. 7, 114-115 (2008).
124. 11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int. 54, 347-357 (2009).
125. 11C-PIB positron emission tomography study. Ann. Neurol. 60, 145-147 (2006).
126. 18F]FDG PET study. Neurology 68, 501-508 (2007).
127. Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Någren K, Rinne JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 72, 1504-1511 (2009).
128. 11C]PIB uptake is increased in mild cognitive impairment. Neurology 68, 1603-1606 (2007).
129. Forsberg A, Engler H, Almkvist O et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 1456-1465 (2008).
130. Pike KE, Savage G, Villemagne VL et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer 's disease. Brain 130, 2837-2844 (2007). (Pubitemid 350033975)
131. 11C]PIB uptake and cerebrospinal fluid β-amyloid in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 26, 378-383 (2008).
132. Braskie MN, Klunder AD, Hayashi KM et al. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol. Aging DOI:10.1016/j.neurobiolaging.2008.09.012 (2008) (Epub ahead of print).
133. Small GW, Kepe V, Ercoli LM et al. PET of brain amyloid and tau in mild cognitive impairment.N. Engl. J. Med. 355, 2652-2663 (2006). (Pubitemid 44969124)
134. 18F-FDDNP PET. J. Nucl. Med. 50, 191-197 (2009). •• Recent study directly comparing the two most common tracers available for in vivo amyloid imaging.
135. Thompson PW, Ye L, Morgenstern JL et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J. Neurochem. 109, 623-630 (2009).
136. Rowe, CC, Ackerman U, Browne W et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7, 129-135 (2008).
137. 18F-BAY94-9172. J. Nucl. Med. 50, 309-315 (2009).
138. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J. Nucl. Med. 50, 818-822 (2009).
139. 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques. Nucl. Med. Biol. 36, 411-417 (2009).
140. 11C]PIB. Bioorg. Med. Chem. Lett. 19, 602-605 (2009).
141. 123I]Iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am. J. Psychiatry 159, 474-476 (2002).
142. El Fakhri G, Kijewski MF, Johnson KA et al. MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch. Neurol. 60, 1066-1072 (2003). (Pubitemid 36975792)
143. Arnaiz E, Jelic V, Almkvist O et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12, 851-855 (2001). (Pubitemid 32222729)
144. Cabranes JA, De Juan R, Encinas M et al. Relevance of functional neuroimaging in the progression of mild cognitive impairment. Neurol. Res. 26, 496-501 (2004). (Pubitemid 38879231)
145. Borroni B, Anchisi D, Paghera B et al. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol. Aging 27, 24-31 (2006). (Pubitemid 41627946)
146. de Leon MJ, De Santi S, Zinkowski R et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J. Intern. Med. 256, 205-223 (2004). (Pubitemid 39222990)
147. de Leon MJ, Mosconi L, Blennow K et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. NY Acad. Sci. 1097, 114-145 (2007). (Pubitemid 47084889)
148. Schmidt R, Ropele S, Pendl B et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J. Neurol. Neurosurg. Psychiatry 79, 1312-1317 (2008) • Study proving the feasibility and supporting the use of multimodal neuroimaging in mild-to-moderate AD.
149. Statistical Parametric Mapping. Wellcome Trust Centre for Neuroimaging (2009). www.fil.ion.ucl.ac.uk/spm
150. Biomedical Imaging Quantification. PMOD Technologies Ltd (2009). www.pmod.com